Skip to content

Study · Animal study (in vivo) · rat · 2017

4 results

Cyclophosphamide induced stomach and duodenal lesions as a NO-system disturbance in rats: L-NAME, L-arginine, stable gastric pentadecapeptide BPC 157.

Luetic K, Sucic M, Vlainic J, Halle ZB, Strinic D, Vidovic T, Luetic F, Marusic M, Gulic S, Pavelic TT, Kokot A, Seiwerth RS and 4 more

Show all authors

Drmic D, Batelja L, Seiwerth S, Sikiric P

Inflammopharmacology2 Mar 2017Cited by 46 (Europe PMC)

PMID28255738 (opens in a new tab)DOI10.1007/s10787-017-0330-7 (opens in a new tab)PepBankPUB-28255738
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats given cyclophosphamide, BPC‑157 attenuated the increased NO level in stomach and duodenal tissue.

    In plain wordsIn rats given cyclophosphamide, BPC‑157 lowered the raised nitric oxide level in stomach and duodenal tissue.

    Peptide
    BPC-157
    Outcome
    DecreaseTissue NO level after cyclophosphamide
    Study

    ratn: not reported in source

    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal or drinking water · until sacrificeAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 therapy (10 µg/kg, 10 ng/kg, intraperitoneally once a day or in drinking water, till the sacrifice) attenuated the increased NO- and MDA-levels
    1 context sentence
    Summary · context
    We revealed a new point with cyclophosphamide (150 mg/kg/day intraperitoneally for 7 days): we counteracted both rat stomach and duodenal ulcers and increased NO- and MDA-levels in these tissues.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats given cyclophosphamide, BPC‑157 attenuated the increased MDA level in stomach and duodenal tissue.

    In plain wordsIn rats given cyclophosphamide, BPC‑157 lowered the raised oxidative stress marker MDA in stomach and duodenal tissue.

    Peptide
    BPC-157
    Outcome
    DecreaseTissue MDA level (oxidative stress) after cyclophosphamide
    Study

    ratn: not reported in source

    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal or drinking water · until sacrificeAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 therapy (10 µg/kg, 10 ng/kg, intraperitoneally once a day or in drinking water, till the sacrifice) attenuated the increased NO- and MDA-levels
    1 context sentence
    Summary · context
    We revealed a new point with cyclophosphamide (150 mg/kg/day intraperitoneally for 7 days): we counteracted both rat stomach and duodenal ulcers and increased NO- and MDA-levels in these tissues.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats given cyclophosphamide, BPC‑157 nullified severe stomach and duodenal ulcers.

    In plain wordsIn rats given cyclophosphamide, BPC‑157 abolished severe stomach and duodenal ulcers.

    Peptide
    BPC-157
    Outcome
    DecreaseStomach and duodenal ulcers after cyclophosphamide
    Study

    ratn: not reported in source

    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal or drinking water · until sacrificeAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 therapy (10 µg/kg, 10 ng/kg, intraperitoneally once a day or in drinking water, till the sacrifice) attenuated the increased NO- and MDA-levels and nullified, in rats, severe cyclophosphamide-ulcers
    1 context sentence
    Summary · context
    We revealed a new point with cyclophosphamide (150 mg/kg/day intraperitoneally for 7 days): we counteracted both rat stomach and duodenal ulcers and increased NO- and MDA-levels in these tissues.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats given cyclophosphamide plus L-NAME, BPC‑157 nullified the even stronger stomach and duodenal lesions.

    In plain wordsIn rats given cyclophosphamide plus L-NAME, BPC‑157 abolished the stronger stomach and duodenal lesions.

    Peptide
    BPC-157
    Outcome
    DecreaseStomach and duodenal lesions after cyclophosphamide plus L-NAME
    Study

    ratn: not reported in source

    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal or drinking water · until sacrificeAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 therapy (10 µg/kg, 10 ng/kg, intraperitoneally once a day or in drinking water, till the sacrifice) attenuated the increased NO- and MDA-levels and nullified, in rats, severe cyclophosphamide-ulcers and even stronger stomach and duodenal lesions after cyclophosphamide + L-NAME (5 mg/kg intra…
    1 context sentence
    Summary · context
    We revealed a new point with cyclophosphamide (150 mg/kg/day intraperitoneally for 7 days): we counteracted both rat stomach and duodenal ulcers and increased NO- and MDA-levels in these tissues.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.